Latest Us Market News

AML3D has completed its initial $4.5 million delivery of two ARCEMY® X systems to Newport News Shipbuilding, the largest US military shipbuilder, with a follow-up order worth $9.9 million underway for early 2027 delivery.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.

Harvest Technology Group has transitioned from assessing to actively executing its international defence market strategy by engaging a US national security advisory firm and appointing Dr Oleksandra Molloy as Defence Strategic Advisor for Europe.

Nova Minerals' US holding company shares and warrants are slated to begin trading on NYSE American on 17 June 2026, with ASX trading of CHESS Depositary Interests following on 18 June, marking a key step in the company’s US redomiciliation.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

Imricor Medical Systems has submitted the third of four Premarket Approval modules to the FDA, marking a key step towards US approval of its MR-guided cardiac ablation devices.

LTR Pharma has locked in Strive Specialties as its exclusive US pharmacy fulfilment partner for ROXUS, marking a critical step towards commercial launch in the US erectile dysfunction market.

Eden Innovations has wrapped up the second tranche of its $4 million institutional placement, issuing over 14 million shares at 18 cents each. The capital injection finalises the raise announced in April, with shares issued under ASX rules and ranking equally with existing stock.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

ArborGen Holdings announces CEO Justin Birch's resignation after three years, appointing Patrick Cumbie as interim CEO while searching for a permanent replacement.